CEN Biotech (CENBF) 10-K 16 Apr 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Apr. 15, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	CEN BIOTECH INC
Entity Central Index Key	0001653821
Trading Symbol	cenb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		25,518,363
Entity Public Float			$ 0
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 3,193	$ 84,978
Property, plant and improvements
Property and equipment, net	166,509	14,576
Improvements in process		1,430,839
Other assets
Other receivable	418,905	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	875,328	775,328
Deferred lease expense		217,210
Intangible assets, net	5,805,771	6,230,583
Total assets	7,314,565	9,020,935
Current liabilities
Accounts payable	206,521	92,842
Accounts payable – related parties		11,986
Loans payable	10,107,205	9,981,883
Loans payable – related parties	1,360,806	838,923
Convertible notes payable	3,597,760	1,461,979
Convertible notes payable- related parties	926,368	2,210,313
Accrued interest	6,860,494	4,540,692
Accrued interest – related parties	946,227	592,901
Accrued expenses	402,377	295,874
Total current liabilities	24,407,758	20,027,393
Patent acquisition liability	1,010,000	5,000,000
Loans payable – related parties, less current portion		300,000
Convertible notes, less current portion	1,545,887	2,208,193
Convertible notes - related parties, less current portion	1,612,313	500,000
Total liabilities	28,575,958	28,035,586
Commitments and contingencies
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,473,363 and 25,131,843 issued and outstanding as of December 31, 2018 and 2017, respectively. No par value.
Additional paid-in capital	14,393,660	9,110,041
Accumulated deficit	(35,655,053)	(28,124,692)
Total shareholders’ deficit	(21,261,393)	(19,014,651)
Total liabilities and shareholders’ deficit	$ 7,314,565	$ 9,020,935

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	25,473,363	25,131,843
Common stock, shares outstanding (in shares)	25,473,363	25,131,843

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses
Consulting fees	$ 297,685	$ 477,747
Consulting fees – related parties	150,778	767,249
Stock based compensation	682,000	7,777,900
General and administrative	1,970,129	2,591,331
Impairment of leasehold improvements	1,270,115	0
Total operating expenses	4,370,707	11,614,227
Loss from operations	(4,370,707)	(11,614,227)
Other (expense) income
Interest expense	(2,440,194)	(2,040,963)
Interest expense – related parties	(430,818)	(336,139)
Interest income	9,395
Change in fair value of patent acquisition liability	(390,000)
Foreign exchange gain (loss)	91,963	(89,125)
Other expense, net	(3,159,654)	(2,466,227)
Net loss	$ (7,530,361)	$ (14,080,454)
Net Loss Per Share:
Basic and diluted (in dollars per share)	$ (0.30)	$ (1.68)
Weighted Average Number of Shares Outstanding
Basic and diluted (in shares)	25,303,654	8,404,391

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2016	100,000	6,851,843
Balances at Dec. 31, 2016	$ 10		$ 82	$ (14,044,238)	$ (14,044,146)
Issuance of restricted stock awards (in shares)		18,280,000
Issuance of restricted stock awards			9,365,100		9,365,100
Distribution (See Note 15)			(255,141)		(255,141)
Special voting shares repurchased (in shares)	(100,000)
Special voting shares repurchased	$ (10)				(10)
Net loss				(14,080,454)	(14,080,454)
Balances (in shares) at Dec. 31, 2017		25,131,843
Balances at Dec. 31, 2017			9,110,041	(28,124,692)	(19,014,651)
Net loss				(7,530,361)	(7,530,361)
Patent acquisition liability modification (See Note 8)			4,380,000		4,380,000
Stock-based compensation (in shares)		20,000
Stock-based compensation			682,000		682,000
Issuance of common stock - interest shares (in shares)		184,400
Issuance of common stock - interest shares			131,878		131,878
Issuance of common stock - consulting (in shares)		137,120
Issuance of common stock - consulting			89,741		89,741
Balances (in shares) at Dec. 31, 2018		25,473,363
Balances at Dec. 31, 2018			$ 14,393,660	$ (35,655,053)	$ (21,261,393)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (7,530,361)	$ (14,080,454)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	14,230	1,767
Amortization	424,812	424,813
Impairment expense	1,270,115	0
Stock-based compensation - employees	682,000	7,777,900
Stock-based compensation - non-employees	89,741	1,587,200
Non-cash interest expense	2,385,807	1,972,836
Non-cash interest expense – related parties	353,326	336,139
Deferred lease expense	217,210	54,302
Change in fair value of patent acquisition liability	390,000
Foreign exchange (gain) loss	(91,963)	89,125
Changes in operating assets and liabilities which provided (used) cash
Other receivable	(196,343)	(222,562)
Accounts payable	95,049	(75,147)
Accounts payable – related parties	65,873	(51,008)
Accrued expenses	106,503	8,227
Net cash used in operating activities	(1,724,001)	(2,176,862)
Cash flows from investing activities
Advance on business acquisition	(100,000)	(350,000)
Leasehold improvements in progress	(5,439)	(160,724)
Net cash used in investing activities	(105,439)	(510,724)
Cash flows from financing activities
Issuance of loans payable	380,000
Repayment of loans payable	(230,000)
Issuance of loans payable – related parties	225,000
Repayment of loans payable – related parties		(10,000)
Issuance of convertible notes	1,565,887	2,220,193
Repayment of convertible notes	(21,600)
Issuance of convertible notes - related parties		500,000
Repayment of convertible notes - related parties	(171,632)
Preferred stock buy-back		(10)
Net cash provided by financing activities	1,747,655	2,710,183
Net (decrease) increase in cash and cash equivalents	(81,785)	22,597
Cash and cash equivalents, beginning of year	84,978	62,381
Cash and cash equivalents, end of year	3,193	84,978
Supplemental cash flows disclosures
Cash paid for interest	66,006	68,127
Non-cash transactions - investing and financing activities
Patent acquisition liability modification	4,380,000
Conversion of rents due to convertible loan		271,512
Accrued expense converted to convertible loans		552,935
Acquisition of equipment in exchange for loan payable from R&D Labs, a related party		300,000
Sale of equipment in exchange for note receivable - related party		44,859
Distribution		$ 255,141

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 CEN Biotech, Inc. (“CEN”) was incorporated in Canada on August 4, 2013 February 29, 2016, $5,807,665 January 1, 2016 The consolidated financial statements also include the accounts of CEN Holdings, Inc. (“CEN Holdings”), a Michigan corporation that was incorporated on May 13, 2016 March 20, 2017. August 22, 2017 Prior to the Spin Off Distribution on February 29, 2016, March 11, 2015, CEN is focused on the manufacturing, production and development of products within the cannabis industry, including the LED lighting technology and hemp products. The Company intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products. CEN intends to explore the usage of hemp, which it intends to cultivate for usage in industrial, medical and food products.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 2 Consolidation CEN’s consolidated financial statements include the accounts of CEN, CEN Holdings, and Eastern Starr (collectively, the “Company”). CEN Holdings’ purpose was to ease and facilitate US banking transactions through March 2017. Basis of Accounting The Company’s consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar. Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements (including intangible assets), and the reported amounts of expenses during the reporting period, including stock-based compensation. Accordingly, actual results may Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three Property, Plant and Improvements Property, plant and improvements are recorded at cost. Depreciation and amortization is provided using the straight-line method over the estimated useful lives or term of the assets, which range from 5 7 The cost of asset additions and improvements that extend the useful lives of property, plant and improvements are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not Intangible Assets Intangible assets include a patent with a definite useful life and is amortized over 16 may not may not Impairment of Long-Lived Assets A long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not 6 2018 no December 31, 2017. Research and Development Expenditures CEN expenses all research and development expenses when incurred. Research and development expenses were approximately $41,000 $32,000 2018 2017, Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities. Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are converted in the Company’s consolidated financial statements to U.S. dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the consolidated statements of operations. Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, 718 718 2018 07, January 1, 2018, Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. 2018 2017, not

Note 3 - New Accounting Standar

Note 3 - New Accounting Standards	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 3 Adoption of New Accounting Standards On January 1, 2018, not no In January 2016, No. 2016 01, December 15, 2017, not In June 2018, No. 2018 07, 718 December 15, 2018, not Accounting Standards Issued but Not In February 2016, December 15, 2018 January 1, 2019 $256,000 not

Note 4 - Going Concern Uncertai

Note 4 - Going Concern Uncertainty Management Plans	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 4 The accompanying consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $35,655,053 December 31, 2018 no not not 9, 10, 11, 12. no not The Company’s cash position may not

Note 5 - Property, Plant and Im

Note 5 - Property, Plant and Improvements, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 Property and equipment, net consists of the following as of December 31: 2018 2017 Leasehold improvements $ 166,163 - Furniture and equipment 17,668 17,668 Accumulated depreciation and amortization (17,322 ) (3,092 ) Net property, plant and improvements $ 166,509 $ 14,576 Depreciation and amortization expense was $14,230 $1,767 December 31, 2018 2017,

Note 6 - Improvements in Proces

Note 6 - Improvements in Process	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Improvements in Process [Text Block]	NOTE 6 Property and improvements in development as of December 31, 2017, 20 An impairment assessment during the fourth 2018 20 $1,270,115 2018 no 2017. During 2018, $160,724 December 31, 2017,

Note 7 - Advances to CEN Biotec

Note 7 - Advances to CEN Biotech Ukraine	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Advances to Related Party [Text Block]	NOTE 7 At December 31, 2018 2017, $875,328 $775,328 15

Note 8 - Intangible Assets

Note 8 - Intangible Assets	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 8 On September 12, 2016, August 31, 2016, Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 135 $2,161,467 1517 1525 $202,666. The patent intangible remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 between the Company and the Sellers, CEN has reaffirmed the rights to use the patented technology. In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not $200,000 In March 2018, $5 one million September 30, 2018. October 4, 2018, December 15, 2018. 24, December 31, 2019. $4,380,000 December 31, 2018, $1,010,000. The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no The intangible assets consists of the following as of December 31: 2018 2017 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (991,229 ) (566,417 ) Net $ 5,805,771 $ 6,230,583 As of December 31, 2018 2017, no The lighting patent is being amortized straight-line over 16 $424,812 2031, $283,215 2032.

Note 9 - Loans Payable

Note 9 - Loans Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 9 Loans payable consist of the following at December 31: 2018 2017 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment. $ 9,675,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018. 282,205 306,883 Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on January 16, 2019. 50,000 - Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on March 16, 2019. 100,000 - Total loans payable (all current) $ 10,107,205 $ 9,981,883 We are in default of $9,675,000 $9,000. not During 2018, 76,400 $54,388 No 2017.

Note 10 - Loans Payable - Relat

Note 10 - Loans Payable - Related Parties	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Loans Payable to Related Party [Text Block]	NOTE 10 Loans payable - related party consists of the following at December 31: 2018 2017 Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018. $ 234,306 $ 237,423 Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018. 601,500 601,500 Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse. 300,000 300,000 Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 100,000 - Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 75,000 - Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 50,000 - Total loans payable - related party 1,360,806 1,138,923 Less: current portion 1,360,806 838,923 Long-term portion loans payable - related party $ - $ 300,000 In March 2018, Attributable related party accrued interest was $357,373 $248,100 December 31, 2018 2017, $184,250 $89,892 2018 2017, During 2018, 108,000 $77,490 No 2017.

Note 11 - Convertible Notes

Note 11 - Convertible Notes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Long-term Debt [Text Block]	NOTE 11 Convertible notes payable consists of the following at December 31: 2018 2017 Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand. $ 809,755 $ 880,567 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,684,018 common shares, maturing at various dates between May 2018 and November 2020. 4,333,892 2,789,605 Total convertible notes payable 5,143,647 3,670,172 Less current portion 3,597,760 1,461,979 Convertible notes payable, less current portion $ 1,545,887 $ 2,208,193 These notes may 3,019,851 As of April 15, 2019, $1,318,287 827,402

Note 12 - Convertible Notes - R

Note 12 - Convertible Notes - Related Parties	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Long-term Convertible Notes Related Party [Text Block]	NOTE 12 Convertible notes - related party consists of the following at December 31: 2018 2017 Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 548,980 common shares with maturity dates of March 31, 2019. 878,368 1,050,000 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019. 48,000 48,000 Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020 224,191 224,191 Total convertible notes payable - related party 2,538,681 2,710,313 Less current portion 926,368 2,210,313 Convertible notes payable - related party, less current portion $ 1,612,313 $ 500,000 In March 2018, Attributable related party accrued interest was $588,854 $344,801 December 31, 2018 2017, $246,568 $246,247 2018 2017, These notes may 1,586,676 As of April 15, 2019, $926,368 578,980

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 13 A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the years ended December 31: 2018 2017 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 % As of December 31, 2018, $36,500,000 may 20 2034. may not not December 31: 2018 2017 Deferred tax asset - net operating losses $ 9,700,000 $ 5,900,000 Deferred tax asset valuation allowance (9,700,000 ) (5,900,000 ) Net deferred tax asset $ - $ - All other temporary differences are immaterial both individually and in the aggregate to the consolidated financial statements. Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of December 31, 2018, no no no 2015.

Note 14 - Shareholders' Deficit

Note 14 - Shareholders' Deficit Stock Activity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 14 The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no On December 11, 2017, 99,286 $9.93. 500 As of December 31, 2018, 4,606,527 On November 27, 2018, 714 $0.07. 500

Note 15 - Related Party Transac

Note 15 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 15 The Company has received loans from several related parties, as described above in Notes 10 12. There are advances of $875,328 $775,328 December 31, 2018 2017, December 3, 2017, 51% December 3, 2017, 25.5% December 14, 2017, 51% not April 15, 2019, On July 12, 2017, 5% During the years ended December 31, 2018 2017, $150,778 $767,249, December 31, 2017, $11,986 No December 31, 2018. During 2017, $300,000 $255,141 $44,859 10 2017 2026. No December 31, 2018, 2017.

Note 16 - Lease (Including Rela

Note 16 - Lease (Including Related Parties)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 16 The Company leases 20 10.4 two one 27,000 one 53,000 4,000 6, 2018. The 20 September 1, 2013 $339,000, December 31, 2016, $552,934, January 2017, $4,000 five $824,446 5 6, 2018. 2018 2017, $253,695 $105,332, Amounts due at December 31, 2018 three Year Amount 2019 $ 36,451 2020 36,451 2021 36,451 Total $ 109,353 The Company also leases office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. Under the lease agreement effective October 1, 2017, $2,608 September 2022, $3,390 2018 2017, $24,000 $6,000, Amounts due at December 31, 2018 five Year Amount 2019 $ 22,940 2020 22,940 2021 22,940 2022 24,660 2023 29,818 Thereafter 111,819 Total $ 235,117

Note 17 - Stock Based Compensat

Note 17 - Stock Based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 17 Adoption of Equity Compensation Plan On November 29, 2017, 2017 20,000,000 Equity Compensation Grants On November 30, 2017, one 20,000 In addition, as part of this one 1,000,000 550,000 36 1,870,000 1,330,000 36 On June 7, 2018, one 20,000 On June 19, 2018, 125,000 On December 31, 2018, 12,120 Employment Agreements On November 30, 2017, four • Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 8,750,000 7,400,000 36 • Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 1,250,000 325,000 36 • Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 4,500,000 4,140,000 36 • Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 750,000 300,000 36 Restricted Stock Awards The grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $102,141 $11,333,600 2018 2017, 2017, 14,317,500 3,962,500 three 157,120 2018, 1,350,000 Compensation expense, broken out by allocation, recognized in connection with the restricted stock awards was as follows for the years ended December 31: 2018 2017 Stock Based Compensation $ 682,000 $ 7,777,900 Professional fees 12,241 806,000 Security consulting - related party - 620,000 Legal 77,500 161,200 Total $ 771,741 $ 9,365,100 Non-vested restricted stock award activity for the years ended December 31, 2018 2017 Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2017 - $ - - Granted 18,280,000 0.62 3.00 Vested (14,317,500 ) 0.62 - Forfeited - - - Non-vested at December 31, 2017 3,962,500 0.62 2.92 Granted 157,120 0.65 - Vested (1,507,120 ) 0.62 - Forfeited - - - Non-vested at December 31, 2018 2,612,500 $ 0.62 2.00 The fair value of the restricted stock grants was based on the valuation of a third $1,298,900 December 31, 2018.

Note 18 - Eastern Starr

Note 18 - Eastern Starr	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 18 On August 22, 2017, $3,000

Note 19 - Other Receivable

Note 19 - Other Receivable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 19 In May 2017, June 30, 2018, $1,000,000 $733,000 June 30, 2020 ( 2% No December 31, 2018. may

Note 20 - Net Loss Per Share

Note 20 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 20 During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of December 31, 2018 2017. December 31, 2018 2017 2018 2017 Convertible debt 4,154,760 2,962,811

Note 21 - Contingency

Note 21 - Contingency	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 21 In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 10 May 4, 2016 5 not

Note 22 - Fair Value Disclosure

Note 22 - Fair Value Disclosures	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 22 Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The fair value of the Company’s financial instruments are as follows: Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2018: Cash and cash equivalents $ 3,193 $ - $ 3,193 $ - $ 3,193 Other receivables $ 418,905 $ - $ - $ 418,905 $ 418,905 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 875,328 $ - $ - $ 875,328 $ 875,328 Loans payable $ 10,107,205 $ - $ - $ 10,107,205 $ 10,107,205 Loans payable – related parties $ 1,360,806 $ - $ - $ - $ - Patent acquisition liability $ 1,010,000 $ - $ - $ 1,010,000 $ 1,010,000 Convertible notes payable $ 5,143,647 $ - $ - $ 5,534,810 $ 5,534,810 Convertible notes payable – related parties $ 2,538,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2017: Cash and cash equivalents $ 84,978 $ - $ 84,978 $ - $ 84,978 Other receivables $ 222,562 $ - $ - $ 222,562 $ 222,562 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 775,328 $ - $ - $ 775,328 $ 775,328 Loans payable $ 9,981,883 $ - $ - $ 9,981,883 $ 9,981,883 Loans payable – related parties $ 1,138,923 $ - $ - $ - $ - Convertible notes payable $ 3,670,172 $ - $ - $ 3,831,760 $ 3,831,760 Convertible notes payable – related parties $ 2,710,313 $ - $ - $ - $ - The fair values of other receivables (including related accrued interest), note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments. The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates. The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates. It is not The fair value of the patent acquisition liability in 2018 3 rd

Note 23 - Share Purchase Agreem

Note 23 - Share Purchase Agreement	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Share Purchase Agreement [Text Block]	NOTE 23 On July 31, 2018, 70% 2,500,000 April 15, 2019, not

Note 24 - Subsequent Events

Note 24 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 24 On April 3, 2019, August 31, 2016, September 12, 2016, December 31, 2019. Since December 31, 2018 7 $200,675 125,422

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Consolidation CEN’s consolidated financial statements include the accounts of CEN, CEN Holdings, and Eastern Starr (collectively, the “Company”). CEN Holdings’ purpose was to ease and facilitate US banking transactions through March 2017.
Basis of Accounting, Policy [Policy Text Block]	Basis of Accounting The Company’s consolidated financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America. The functional currency of the Company is the U.S. dollar.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Assumptions The accompanying consolidated financial statements include certain estimates and assumptions which affect the reported amounts of assets and liabilities at the date of the financial statements (including intangible assets), and the reported amounts of expenses during the reporting period, including stock-based compensation. Accordingly, actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For purposes of the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with a maturity of three
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Improvements Property, plant and improvements are recorded at cost. Depreciation and amortization is provided using the straight-line method over the estimated useful lives or term of the assets, which range from 5 7 The cost of asset additions and improvements that extend the useful lives of property, plant and improvements are capitalized. Routine maintenance and repair items are charged to current operations. The original cost and accumulated depreciation of asset dispositions are removed from the accounts and any gain or loss is reflected in the statement of operations in the period of disposition. The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment is performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset's fair value and its carrying value. If quoted market prices are not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Intangible assets include a patent with a definite useful life and is amortized over 16 may not may not
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets A long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not 6 2018 no December 31, 2017.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenditures CEN expenses all research and development expenses when incurred. Research and development expenses were approximately $41,000 $32,000 2018 2017,
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred income tax assets and liabilities are computed annually for differences between the financial statement and income tax bases of assets and liabilities that will result in taxable or deductible amounts in the future, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the year plus or minus the change during the year in deferred tax assets and liabilities.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions and Balances Foreign currency transactions in Canadian dollars are converted in the Company’s consolidated financial statements to U.S. dollars at the exchange rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are subsequently remeasured at the balance sheet date exchange rate into the functional currency. All gains and losses resulting from the settlement of foreign currency transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies are included in the consolidated statements of operations.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The fair value of restricted stock awards granted to employees and non-employees is determined on the grant date and compensation is recognized ratably over the requisite service period equal to the fair value of the award. The Company accounts for restricted stock awards issued to employees and non-employees in accordance with the authoritative guidance in ASC Topic 718, 718 718 2018 07, January 1, 2018,
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Net loss per common share is computed pursuant to ASC 260 10 45. 2018 2017, not

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Improvements, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	2018 2017 Leasehold improvements $ 166,163 - Furniture and equipment 17,668 17,668 Accumulated depreciation and amortization (17,322 ) (3,092 ) Net property, plant and improvements $ 166,509 $ 14,576

Note 8 - Intangible Assets (Tab

Note 8 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2018 2017 Lighting patent $ 6,797,000 $ 6,797,000 Accumulated amortization (991,229 ) (566,417 ) Net $ 5,805,771 $ 6,230,583

Note 9 - Loans Payable (Tables)

Note 9 - Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Short-term Debt [Table Text Block]	2018 2017 Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment. $ 9,675,000 $ 9,675,000 Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018. 282,205 306,883 Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on January 16, 2019. 50,000 - Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on March 16, 2019. 100,000 - Total loans payable (all current) $ 10,107,205 $ 9,981,883

Note 10 - Loans Payable - Rel_2

Note 10 - Loans Payable - Related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Loans Payable to Related Party [Table Text Block]	2018 2017 Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018. $ 234,306 $ 237,423 Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018. 601,500 601,500 Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse. 300,000 300,000 Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 100,000 - Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 75,000 - Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on March 16, 2019. 50,000 - Total loans payable - related party 1,360,806 1,138,923 Less: current portion 1,360,806 838,923 Long-term portion loans payable - related party $ - $ 300,000

Note 11 - Convertible Notes (Ta

Note 11 - Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2018 2017 Convertible note payable, bearing interest at 7% per annum with conversion rights for 335,833 common shares. This is due on demand. $ 809,755 $ 880,567 Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,684,018 common shares, maturing at various dates between May 2018 and November 2020. 4,333,892 2,789,605 Total convertible notes payable 5,143,647 3,670,172 Less current portion 3,597,760 1,461,979 Convertible notes payable, less current portion $ 1,545,887 $ 2,208,193

Note 12 - Convertible Notes -_2

Note 12 - Convertible Notes - Related Parties (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Convertible Notes Payable to Related Party [Table Text Block]	2018 2017 Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020. $ 1,388,122 $ 1,388,122 Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 548,980 common shares with maturity dates of March 31, 2019. 878,368 1,050,000 Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019. 48,000 48,000 Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020 224,191 224,191 Total convertible notes payable - related party 2,538,681 2,710,313 Less current portion 926,368 2,210,313 Convertible notes payable - related party, less current portion $ 1,612,313 $ 500,000

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 Income tax benefit at Canadian statutory rate 26.5 % 26.5 % Valuation allowance (26.5 %) (26.5 %) Effective income tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2018 2017 Deferred tax asset - net operating losses $ 9,700,000 $ 5,900,000 Deferred tax asset valuation allowance (9,700,000 ) (5,900,000 ) Net deferred tax asset $ - $ -

Note 16 - Lease (Including Re_2

Note 16 - Lease (Including Related Parties) (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Amount 2019 $ 36,451 2020 36,451 2021 36,451 Total $ 109,353 Year Amount 2019 $ 22,940 2020 22,940 2021 22,940 2022 24,660 2023 29,818 Thereafter 111,819 Total $ 235,117

Note 17 - Stock Based Compens_2

Note 17 - Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2018 2017 Stock Based Compensation $ 682,000 $ 7,777,900 Professional fees 12,241 806,000 Security consulting - related party - 620,000 Legal 77,500 161,200 Total $ 771,741 $ 9,365,100
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of Shares Weighted- Average Grant Date Fair Value per Share Weighted- Average Remaining Contractual Term (Years) Non-vested at January 1, 2017 - $ - - Granted 18,280,000 0.62 3.00 Vested (14,317,500 ) 0.62 - Forfeited - - - Non-vested at December 31, 2017 3,962,500 0.62 2.92 Granted 157,120 0.65 - Vested (1,507,120 ) 0.62 - Forfeited - - - Non-vested at December 31, 2018 2,612,500 $ 0.62 2.00

Note 20 - Net Loss Per Share (T

Note 20 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2018 2017 Convertible debt 4,154,760 2,962,811

Note 22 - Fair Value Disclosu_2

Note 22 - Fair Value Disclosures (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measured at Reporting Date Using Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2018: Cash and cash equivalents $ 3,193 $ - $ 3,193 $ - $ 3,193 Other receivables $ 418,905 $ - $ - $ 418,905 $ 418,905 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 875,328 $ - $ - $ 875,328 $ 875,328 Loans payable $ 10,107,205 $ - $ - $ 10,107,205 $ 10,107,205 Loans payable – related parties $ 1,360,806 $ - $ - $ - $ - Patent acquisition liability $ 1,010,000 $ - $ - $ 1,010,000 $ 1,010,000 Convertible notes payable $ 5,143,647 $ - $ - $ 5,534,810 $ 5,534,810 Convertible notes payable – related parties $ 2,538,681 $ - $ - $ - $ - Carrying Amount Level 1 Level 2 Level 3 Fair Value At December 31, 2017: Cash and cash equivalents $ 84,978 $ - $ 84,978 $ - $ 84,978 Other receivables $ 222,562 $ - $ - $ 222,562 $ 222,562 Note receivable - related party $ 44,859 $ - $ - $ 44,859 $ 44,859 Advances to CEN Biotech Ukraine, LLC - related party $ 775,328 $ - $ - $ 775,328 $ 775,328 Loans payable $ 9,981,883 $ - $ - $ 9,981,883 $ 9,981,883 Loans payable – related parties $ 1,138,923 $ - $ - $ - $ - Convertible notes payable $ 3,670,172 $ - $ - $ 3,831,760 $ 3,831,760 Convertible notes payable – related parties $ 2,710,313 $ - $ - $ - $ -

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stockholders' Equity Attributable to Parent, Ending Balance	$ (21,261,393)	$ (19,014,651)	$ (14,044,146)	$ (5,807,665)

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Asset, Useful Life	16 years
Asset Impairment Charges, Total	$ 1,270,115	$ 0
Research and Development Expense, Total	$ 41,000	$ 32,000
Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Note 3 - New Accounting Stand_2

Note 3 - New Accounting Standards (Details Textual) - Subsequent Event [Member]	Jan. 01, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 256,000
Operating Lease, Liability, Total	$ 256,000

Note 4 - Going Concern Uncert_2

Note 4 - Going Concern Uncertainty Management Plans (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit), Ending Balance	$ (35,655,053)	$ (28,124,692)

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Improvements, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 14,230	$ 1,767

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accumulated depreciation and amortization	$ (17,322)	$ (3,092)
Net property, plant and improvements	166,509	14,576
Leasehold Improvements [Member]
Property, plant and equipment, gross	166,163
Furniture and Equipment [Member]
Property, plant and equipment, gross	$ 17,668	$ 17,668

Note 6 - Improvements in Proc_2

Note 6 - Improvements in Process (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Tangible Asset Impairment Charges, Total	$ 1,270,115	$ 1,270,115	$ 0
Transfer of Improvements in Process to Property, Plant and Equipment		$ 160,724

Note 7 - Advances to CEN Biot_2

Note 7 - Advances to CEN Biotech Ukraine (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CEN Biotech Ukraine [Member]
Payments to Fund Long-term Loans to Related Parties	$ 875,328	$ 775,328

Note 8 - Intangible Assets (Det

Note 8 - Intangible Assets (Details Textual) - USD ($)	Sep. 12, 2016	Mar. 31, 2018	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Stock Issued During Period, Value, Purchase of Assets		$ 5,000,000
Development of Acquired Technology, Annual Compensation for Specialist	$ 200,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred			$ 4,380,000		$ 4,380,000
Adjustments to Additional Paid in Capital, Patent Acquisition Liability Modification			$ 4,380,000		4,380,000
Contingent Consideration Classified as Equity, Fair Value Disclosure					1,010,000
Impairment of Real Estate					$ 0	$ 0
Finite-Lived Intangible Asset, Useful Life					16 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months					$ 424,812
Finite-Lived Intangible Assets, Amortization Expense, after Year Fourteen					$ 283,215
Tesla Digital [Member]
Stock Issued During Period, Shares, Purchase of Assets				1,000,000
Patented Technology [Member]
Stock Issued During Period, Value, Purchase of Assets	5,000,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred	2,161,467
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred	$ 202,666

Note 8 - Intangible Assets - In

Note 8 - Intangible Assets - Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Lighting patent	$ 6,797,000	$ 6,797,000
Accumulated amortization	(991,229)	(566,417)
Net	$ 5,805,771	$ 6,230,583

Note 9 - Loans Payable (Details

Note 9 - Loans Payable (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument, Debt Default, Amount	$ 9,675,000
Equipment Pledged as Collateral	9,000
Stock Issued During Period, Value, New Issues	$ 131,878
Individual Lenders [Member]
Stock Issued During Period, Shares, New Issues	76,400	0
Stock Issued During Period, Value, New Issues	$ 54,388

Note 9 - Loans Payable - Loans

Note 9 - Loans Payable - Loans Payable (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Loans payable	$ 10,107,205	$ 9,981,883
Short-term Loan Payable to Global Holdings International, LLC [Member]
Loans payable	9,675,000	9,675,000
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Loans payable	282,205	306,883
Short-term Loan Payable to an Individual [Member]
Loans payable	50,000
Second Short-term Loan Payable to an Individual [Member]
Loans payable	$ 100,000

Note 9 - Loans Payable - Loan_2

Note 9 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Short-term Loan Payable to Global Holdings International, LLC [Member]
Interest Rate	15.00%	15.00%
Maturity Date	Jun. 30, 2016	Jun. 30, 2016
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Interest Rate	22.00%	22.00%
Maturity Date	Nov. 21, 2018	Nov. 21, 2018
Original Amount	$ 385,000	$ 385,000
Short-term Loan Payable to an Individual [Member]
Maturity Date	Jan. 16, 2019	Jan. 16, 2019
Share Interest (in shares)	2,000	2,000
Second Short-term Loan Payable to an Individual [Member]
Maturity Date	Mar. 16, 2019	Mar. 16, 2019
Share Interest (in shares)	4,000	4,000

Note 10 - Loans Payable - Rel_3

Note 10 - Loans Payable - Related Parties (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Interest Expense, Related Party	$ 430,818	$ 336,139
Stock Issued During Period, Value, New Issues	$ 131,878
Related Parties Lenders [Member]
Stock Issued During Period, Shares, New Issues	108,000	0
Stock Issued During Period, Value, New Issues	$ 77,490
Loans Payable to Related Party [Member]
Interest Payable, Related Party	357,373	$ 248,100
Interest Expense, Related Party	$ 184,250	$ 89,892

Note 10 - Loans Payable - Rel_4

Note 10 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Long-term Debt	$ 1,360,806	$ 1,138,923
Less: current portion	1,360,806	838,923
Long-term portion loans payable - related party		300,000
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	234,306	237,423
Creative Edge [Member]
Long-term Debt	601,500	601,500
R&D Labs Canada, Inc [Member]
Long-term Debt	300,000	300,000
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Long-term Debt	100,000
Director, Alex Tarrabain [Member]
Long-term Debt	75,000
Joseph Byrne [Member]
Long-term Debt	$ 50,000

Note 10 - Loans Payable - Rel_5

Note 10 - Loans Payable - Related Parties - Loans Payable to Related Parties (Details) (Parentheticals) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Bill Chaaban, President of Cen Biotech [Member] | Loans Payable to Related Party [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
Creative Edge [Member] | Loans Payable to Related Party [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
R&D Labs Canada, Inc [Member] | Loans Payable to Related Party [Member]
Interest Rate	8.00%	8.00%
Maturity Date	Oct. 2, 2019	Oct. 2, 2019
Spouse of Joseph Byrne, CEO of CEN Biotech [Member] | Loans Payable to Related Party [Member]
Maturity Date	Mar. 16, 2019	Mar. 16, 2019
Share Interest (in shares)	4,000	4,000
Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%
Maturity Date	Mar. 31, 2019	Mar. 31, 2019
Director, Alex Tarrabain [Member] | Loans Payable to Related Party [Member]
Maturity Date	Mar. 16, 2019	Mar. 16, 2019
Share Interest (in shares)	3,000	3,000
Joseph Byrne [Member] | Loans Payable to Related Party [Member]
Maturity Date	Mar. 16, 2019	Mar. 16, 2019
Share Interest (in shares)	2,000	2,000

Note 11 - Convertible Notes (De

Note 11 - Convertible Notes (Details Textual)	Apr. 15, 2019USD ($)	Dec. 31, 2018
Subsequent Event [Member]
Convertible Debt, Total	$ 200,675
Convertible Debt [Member]
Debt Instrument, Convertible, Number of Equity Instruments		3,019,851
Convertible Debt in Default [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	827,402
Convertible Debt, Total	$ 1,318,287

Note 11 - Convertible Notes - C

Note 11 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Long-term Debt	$ 5,143,647	$ 3,670,172
Less: current portion	3,597,760	1,461,979
Long-term portion loans payable - related party	1,545,887	2,208,193
Convertible Payable 1 [Member]
Long-term Debt	809,755	880,567
Convertible Notes 2 [Member]
Long-term Debt	$ 4,333,892	$ 2,789,605

Note 11 - Convertible Notes -_2

Note 11 - Convertible Notes - Convertible Notes (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Convertible Debt [Member]
Conversion Rights	3,019,851
Convertible Payable 1 [Member] | Convertible Debt [Member]
Interest Rate	7.00%	7.00%
Conversion Rights	335,833	335,833
Convertible Notes 2 [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	2,684,018	2,684,018
Maturing Dates Range	May 2018 and November 2020	May 2018 and November 2020

Note 12 - Convertible Notes -_3

Note 12 - Convertible Notes - Related Parties (Details Textual)	Apr. 15, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Interest Expense, Related Party		$ 430,818	$ 336,139
Subsequent Event [Member]
Convertible Debt, Total	$ 200,675
Convertible Debt Payable to Related Party [Member]
Interest Payable, Related Party		588,854	344,801
Interest Expense, Related Party		$ 246,568	$ 246,247
Debt Instrument, Convertible, Number of Equity Instruments		1,586,676
Convertible Debt Payable to Related Party [Member] | Subsequent Event [Member]
Convertible Debt, Total	$ 926,368
Convertible Debt to Related Party in Default [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	578,980

Note 12 - Convertible Notes -_4

Note 12 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Long-term Debt	$ 2,538,681	$ 2,710,313
Less: current portion	926,368	2,210,313
Long-term portion loans payable - related party	1,612,313	500,000
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	1,388,122	1,388,122
Director, Harold Aubrey de Lavenu [Member]
Long-term Debt	878,368	1,050,000
Director, Alex Tarrabain [Member]
Long-term Debt	48,000	48,000
Joseph Byrne [Member]
Long-term Debt	$ 224,191	$ 224,191

Note 12 - Convertible Notes -_5

Note 12 - Convertible Notes - Related Parties - Convertible Notes Payable to Related Parties (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Director, Harold Aubrey de Lavenu [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	548,980	548,980
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	30,000	30,000
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Convertible Debt Payable to Related Party [Member]
Conversion Rights	1,586,676
Convertible Debt Payable to Related Party [Member] | Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	867,576	867,576
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020
Convertible Debt Payable to Related Party [Member] | Joseph Byrne [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	140,120	140,120
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual)	Dec. 31, 2018USD ($)
Operating Loss Carryforwards, Total	$ 36,500,000

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income tax benefit at Canadian statutory rate	26.50%	26.50%
Valuation allowance	(26.50%)	(26.50%)
Effective income tax rate	0.00%	0.00%

Note 13 - Income Taxes - Deferr

Note 13 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax asset - net operating losses	$ 9,700,000	$ 5,900,000
Deferred tax asset valuation allowance	(9,700,000)	(5,900,000)
Net deferred tax asset

Note 14 - Shareholders' Defic_2

Note 14 - Shareholders' Deficit Stock Activity (Details Textual)	Nov. 27, 2018$ / sharesshares	Dec. 11, 2017$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017$ / sharesshares
Common Stock, No Par Value | $ / shares			$ 0	$ 0
Common Stock, Shares Authorized to be Issued, Shares			4,606,527
Preferred Stock [Member]
Stock Repurchased and Retired During Period, Shares				100,000
Preferred Stock [Member] | President [Member]
Stock Repurchased and Retired During Period, Shares		99,286
Stock Repurchased, Price Per Share | $ / shares		$ 9.93
Preferred Stock, Voting Rights Per Each Share		500
Preferred Stock [Member] | James Robinson [Member]
Stock Repurchased and Retired During Period, Shares	714
Stock Repurchased, Price Per Share | $ / shares	$ 0.07
Preferred Stock, Voting Rights Per Each Share	500

Note 15 - Related Party Trans_2

Note 15 - Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 03, 2017	Dec. 02, 2017	Jul. 12, 2017
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings		$ 255,141
Long-term Convertible Notes Payable to Multiple Private Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage					5.00%
CEN Biotech Ukraine [Member]
Business Acquisition, Percentage of Voting Interests Acquired	51.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total	$ 875,328	775,328
Percentage of Related Party's Equity Interest Owned by Director			25.50%	51.00%
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings		255,141
Notes Receivable, Related Parties		44,859
Board Members and Officers [Member] | Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction	150,778	767,249
Due to Related Parties, Total	$ 0	11,986
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties		$ 300,000

Note 16 - Lease (Including Re_3

Note 16 - Lease (Including Related Parties) (Details Textual)	Oct. 01, 2017CAD ($)	Sep. 01, 2013CAD ($)	Sep. 30, 2022USD ($)	Jan. 31, 2017CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2014a
General and Administrative Expense [Member]
Operating Leases, Rent Expense, Total					$ 253,695	$ 105,332
Convertible Debt Issued to Lessor's Creditor [Member]
Convertible Debt, Total							$ 824,446
Lease Arrangement, 20 North Rear Road [Member]
Area of Land | a									10.4
Operating Lease Annual Rent		$ 339,000
Accrued Rent								$ 552,934
Operating Lease, Monthly Rent				$ 4,000
Lessee, Operating Lease, Term of Contract							5 years
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent	$ 2,608
Operating Leases, Rent Expense, Total					$ 24,000	$ 6,000
Leases Office Space from R&D Labs Canada, Inc [Member] | Scenario, Forecast [Member]
Operating Lease, Monthly Rent			$ 3,390

Note 16 - Lease (Including Re_4

Note 16 - Lease (Including Related Parties) - Future Minimum Operating Lease Payments (Details)	Dec. 31, 2018USD ($)
Lease Arrangement, 20 North Rear Road [Member]
2019	$ 36,451
2020	36,451
2021	36,451
Total	109,353
2019	36,451
2020	36,451
2021	36,451
Leases Office Space from R&D Labs Canada, Inc [Member]
2019	22,940
2020	22,940
2021	22,940
Total	235,117
2019	22,940
2020	22,940
2021	22,940
2022	24,660
2023	29,818
Thereafter	$ 111,819

Note 17 - Stock Based Compens_3

Note 17 - Stock Based Compensation (Details Textual) - USD ($)	Dec. 31, 2018	Jun. 19, 2018	Jun. 07, 2018	Nov. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Nov. 29, 2017	Dec. 31, 2016
Stock Issued During Period, Shares, Issued for Services	12,120	125,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 1,298,900				$ 1,298,900
President [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				8,750,000
President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				7,400,000
Chief Executive Officer [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				1,250,000
Chief Executive Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				325,000
Vice President [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				750,000
Vice President [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				300,000
Senior Executive Vice President and Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				4,500,000
Senior Executive Vice President and Chief Financial Officer [Member] | Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				4,140,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					157,120	18,280,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					1,507,120	14,317,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant DateFair Value					$ 102,141	$ 11,333,600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	2,612,500				2,612,500	3,962,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					157,120
Restricted Stock [Member] | Vesting Pro-rate Over the Requisite Service Period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance						3,962,500
Restricted Stock [Member] | Additional Vested Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					1,350,000
Restricted Stock [Member] | President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Vice President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Senior Executive Vice President and Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Director, Harold Aubrey de Lavenu [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Director, Alex Tarrabain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Director, Ameen Ferris [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] | Director Usamakh Saadikh [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			20,000
Restricted Shares Issued for Security Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				1,330,000
Restricted Shares Issued for Security Consulting Services [Member] | Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				550,000
2017 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance							20,000,000

Note 17 - Stock Based Compens_4

Note 17 - Stock Based Compensation - Compensation Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Compensation expense	$ 771,741	$ 9,365,100
Stock Based Compensation [Member]
Compensation expense	682,000	7,777,900
Professional Fees [Member]
Compensation expense	12,241	806,000
Security Consulting, Related Party [Member]
Compensation expense		620,000
Legal [Member]
Compensation expense	$ 77,500	$ 161,200

Note 17 - Stock Based Compens_5

Note 17 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Non-vested, number of share (in shares)	3,962,500
Non-vested, weithged average grant date fair value (in dollars per share)	$ 0.62
Non-vested, weighted average remaining contractual term (Year)	2 years	2 years 335 days
Granted, number of share (in shares)	157,120	18,280,000
Granted, weithged average grant date fair value (in dollars per share)	$ 0.65	$ 0.62
Granted, weighted average remaining contractual term (Year)		3 years
Vested, number of share (in shares)	(1,507,120)	(14,317,500)
Vested, weithged average grant date fair value (in dollars per share)	$ 0.62	$ 0.62
Forfeited, number of share (in shares)
Forfeited, weithged average grant date fair value (in dollars per share)
Non-vested, number of share (in shares)	2,612,500	3,962,500
Non-vested, weithged average grant date fair value (in dollars per share)	$ 0.62	$ 0.62

Note 18 - Eastern Starr (Detail

Note 18 - Eastern Starr (Details Textual)	Aug. 22, 2017USD ($)
Eastern Starr [Member]
Business Combination, Consideration Transferred, Total	$ 3,000

Note 19 - Other Receivable (Det

Note 19 - Other Receivable (Details Textual) - Line of Credit to Clear Com [Member]	May 31, 2017USD ($)	May 31, 2017CAD ($)
Unfunded Line of Credit Commitment, Maximum	$ 733,000	$ 1,000,000
Receivables, Interest Rate	2.00%	2.00%
Allowance for Doubtful Accounts Receivable, Ending Balance	$ 0

Note 20 - Net Loss Per Share -

Note 20 - Net Loss Per Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	4,154,760	2,962,811

Note 22 - Fair Value Disclosu_3

Note 22 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Reported Value Measurement [Member]
Cash and cash equivalents	$ 3,193	$ 84,978
Other receivables	418,905	222,562
Note receivable - related party	44,859	44,859
Ukraine, LLC - related party	875,328	775,328
Loans payable	10,107,205	9,981,883
Loans payable – related parties	1,360,806	1,138,923
Patent acquisition liability	1,010,000
Convertible notes payable	5,143,647	3,670,172
Convertible notes payable – related parties	2,538,681	2,710,313
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	3,193	84,978
Other receivables	418,905	222,562
Note receivable - related party	44,859	44,859
Ukraine, LLC - related party	875,328	775,328
Loans payable	10,107,205	9,981,883
Loans payable – related parties
Patent acquisition liability	1,010,000
Convertible notes payable	5,534,810	3,831,760
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents
Other receivables
Note receivable - related party
Ukraine, LLC - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	3,193	84,978
Other receivables
Note receivable - related party
Ukraine, LLC - related party
Loans payable
Loans payable – related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable – related parties
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Other receivables	418,905	222,562
Note receivable - related party	44,859	44,859
Ukraine, LLC - related party	875,328	775,328
Loans payable	10,107,205	9,981,883
Loans payable – related parties
Patent acquisition liability	1,010,000
Convertible notes payable	5,534,810	3,831,760
Convertible notes payable – related parties

Note 23 - Share Purchase Agre_2

Note 23 - Share Purchase Agreement (Details Textual) - AstralENERGY [Member]	Jul. 31, 2018shares
Business Acquisition, Percentage of Voting Interests Acquired	70.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,500,000

Note 24 - Subsequent Events (De

Note 24 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Apr. 15, 2019USD ($)shares
Convertible Debt, Total | $	$ 200,675
Debt Conversion Rights, Common Stock, Shares | shares	125,422